Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Giezen (2008)
Optimizing platelet inhibitionEuropean Heart Journal, 29
R. Brown, D. Spina, C. Page (2008)
Adenosine receptors and asthmaBritish Journal of Pharmacology, 153
B. Springthorpe, Andrew Bailey, P. Barton, Timothy Birkinshaw, R. Bonnert, R. Brown, Dave Chapman, J. Dixon, S. Guile, R. Humphries, Simon Hunt, F. Ince, A. Ingall, I. Kirk, P. Leeson, P. Leff, Richard Lewis, B. Martin, D. Mcginnity, M. Mortimore, S. Paine, G. Pairaudeau, Anil Patel, A. Rigby, R. Riley, Barry Teobald, W. Tomlinson, P. Webborn, P. Willis (2007)
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.Bioorganic & medicinal chemistry letters, 17 21
van Giezen (2008)
Optimizing platelet inhibitionEur Heart J Suppl, 10
L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. Braun, J. Jakubowski, A. Sugidachi, K. Winters, A. Siegbahn (2007)
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.European heart journal, 29 1
J. Nowak, J. Murray, J. Oates, G. FitzGerald (1987)
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes.Circulation, 76 1
Kuliczkowski (2009)
Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of CardiologyEur Heart J, 30
S. Gottlieb, D. Brater, I. Thomas, E. Havranek, R. Bourge, S. Goldman, Farere Dyer, Miguel Gómez, D. Bennett, B. Ticho, E. Beckman, W. Abraham (2002)
BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic TherapyCirculation: Journal of the American Heart Association, 105
E. Falk, P. Shah, V. Fuster (1995)
Coronary plaque disruption.Circulation, 92 3
M. Hashemzadeh, M. Furukawa, S. Goldsberry, M. Movahed (2008)
Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.Experimental and clinical cardiology, 13 4
C. Zhan, Jie Yang, Xianchi Dong, Yue-Lan Wang (2007)
Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.Journal of molecular graphics & modelling, 26 1
S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.The New England journal of medicine, 345 7
S. Pitsilos, J. Hunt, E. Mohler, Anand Prabhakar, M. Poncz, Jennine Dawicki, T. Khalapyan, Megan L.Wolfe, R. Fairman, M. Mitchell, J. Carpenter, M. Golden, D. Cines, B. Sachais (2003)
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parametersThrombosis and Haemostasis, 90
S. Fateh‐Moghadam, Zonyang Li, S. Ersel, T. Reuter, P. Htun, U. Plöckinger, W. Bocksch, R. Dietz, M. Gawaz (2005)
Platelet Degranulation Is Associated With Progression of Intima-Media Thickness of the Common Carotid Artery in Patients With Diabetes Mellitus Type 2Arteriosclerosis, Thrombosis, and Vascular Biology, 25
M. Hoffman, D. Monroe (2007)
Coagulation 2006: a modern view of hemostasis.Hematology/oncology clinics of North America, 21 1
P. Minuz, P. Patrignani, S. Gaino, M. Degan, L. Menapace, R. Tommasoli, F. Seta, Marta Capone, S. Tacconelli, S. Palatresi, C. Bencini, C. Vecchio, G. Mansueto, E. Arosio, C. Santonastaso, A. Lechi, A. Morganti, C. Patrono (2002)
Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular DiseaseCirculation: Journal of the American Heart Association, 106
G. Davı̀, P. Gresele, F. Violi, S. Basili, M. Catalano, C. Giammarresi, Raul Volpato, G. Nenci, G. Ciabattoni, C. Patrono (1997)
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.Circulation, 96 1
V. Serebruany (2009)
Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications.The American journal of medicine, 122 5
B. Lerman, L. Belardinelli (1991)
Cardiac Electrophysiology of Adenosine: Basic and Clinical ConceptsCirculation, 83
S. Husted, H. Emanuelsson, S. Heptinstall, P. Sandset, M. Wickens, G. Peters (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.European heart journal, 27 9
S. James, A. Åkerblom, C. Cannon, H. Emanuelsson, S. Husted, H. Katus, A. Skene, P. Steg, R. Storey, R. Harrington, R. Becker, L. Wallentin (2009)
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.American heart journal, 157 4
M. Davies (1996)
Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.Circulation, 94 8
C. Dubois, L. Panicot-Dubois, J. Gainor, B. Furie, B. Furie (2007)
Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model.The Journal of clinical investigation, 117 4
R. Harrington, R. Becker, M. Ezekowitz, T. Meade, C. O'connor, D. Vorchheimer, G. Guyatt (2004)
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126 3 Suppl
H. Koyama, Takaaki Maeno, S. Fukumoto, Takuhito Shoji, T. Yamane, Hisayo Yokoyama, M. Emoto, T. Shoji, H. Tahara, M. Inaba, M. Hino, A. Shioi, T. Miki, Y. Nishizawà (2003)
Platelet P-Selectin Expression Is Associated With Atherosclerotic Wall Thickness in Carotid Artery in HumansCirculation: Journal of the American Heart Association, 108
M. Hashemzadeh, S. Goldsberry, M. Furukawa, A. Khoynezhad, M. Movahed (2009)
ADP receptor-blocker thienopyridines: chemical structures, mode of action and clinical use. A review.The Journal of invasive cardiology, 21 8
T. Jernberg, C. Payne, K. Winters, C. Darstein, J. Brandt, J. Jakubowski, H. Naganuma, A. Siegbahn, L. Wallentin (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.European heart journal, 27 10
C. Cannon, R. Harrington, S. James, D. Ardissino, R. Becker, H. Emanuelsson, S. Husted, H. Katus, M. Keltai, N. Khurmi, F. Kontny, B. Lewis, P. Steg, R. Storey, D. Wojdyla, L. Wallentin (2010)
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 375
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
J. Coppinger, G. Cagney, S. Toomey, T. Kislinger, O. Belton, J. McRedmond, D. Cahill, A. Emili, D. Fitzgerald, P. Maguire (2004)
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.Blood, 103 6
V. Menon, R. Harrington, J. Hochman, C. Cannon, S. Goodman, R. Wilcox, Holger Schünemann, E. Ohman (2004)
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126 3 Suppl
G. Davı̀, I. Catalano, M. Averna, A. Notarbartolo, A. Strano, G. Ciabattoni, C. Patrono (1990)
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.The New England journal of medicine, 322 25
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
G. Davı̀, M. Averna, I. Catalano, C. Barbagallo, Antonella Ganci, A. Notarbartolo, G. Ciabattoni, C. Patrono (1992)
Increased Thromboxane Biosynthesis in Type IIa HypercholesterolemiaCirculation, 85
A. Khoynezhad, M. Movahed, M. Hashemzadeh, Abbas Emaminia, Z. Jalali (2009)
Perioperative management of patients on adenosine diphosphate inhibitors in the era of drug-eluting stents: review of the literature and clinical implications.Current medicinal chemistry, 16 5
Deepak Bhatt (2007)
Intensifying platelet inhibition--navigating between Scylla and Charybdis.The New England journal of medicine, 357 20
C. Cannon, S. Husted, R. Harrington, B. Scirica, H. Emanuelsson, G. Peters, R. Storey (2007)
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.Journal of the American College of Cardiology, 50 19
A. Schömig (2009)
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?The New England journal of medicine, 361 11
G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, E. Romagnoli, G. Sangiorgi, D. Angiolillo, M. Valgimigli, L. Testa, F. Gaita, I. Sheiban (2011)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.International journal of cardiology, 150 3
G. Minno, G. Davı̀, M. Margaglione, F. Cirillo, E. Grandone, G. Ciabattoni, I. Catalano, P. Strisciuglio, G. Andria, C. Patrono (1993)
Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.The Journal of clinical investigation, 92 3
Current clinical guidelines recommend dual antiplatelet agents namely aspirin and clopidogrel for the treatment of patients suffering from acute coronary syndrome (ACS). But the efficacy of clopidogrel is variable as it is a pro‐drug, which has to be metabolized to become an active drug thus exhibiting variable platelet inhibition, increases risk of bleeding, stent thrombosis, and ischemia. To overcome this limitation, prasugrel was developed with increased antiplatelet activity thereby reducing the risk of myocardial ischemia and stent thrombosis. This action of prasugrel was associated with an increased risk of major bleeding. Finally, a novel reversible and direct‐acting oral adenosine diphosphate (ADP) receptor antagonist, ticagrelor was developed that showed consistent and increased P2Y12 inhibition with similar incidence of bleeding but greater reduction in cardiac events compared to clopidogrel. The focus of this article is to review ticagrelor as a new class of P2Y12 inhibitor. (J Interven Cardiol 2011;24:199–207)
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.